The ANNEXA trial compared andexanet alfa, a modified recombinant inactive form of human factor Xa, which binds and sequesters factor Xa inhibitors, with usual care (85.5% receiving prothrombin complex concentrates) on haematoma volume expansion in patients receiving a factor Xa inhibitor within 15 h before an acute intracerebral haemorrhage.27 About 90% of patients had AF, 21% stroke, and 12% MI. The gene discussed is F2; the disease is atrial fibrillation.